培美替尼治疗胆管癌的效果如何？

Pemetinib (also known as pemetinib, English trade name: pemazyre) is a selective fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1, FGFR2, and FGFR3. This time, the FDA approved the marketing of pemetinib for the targeted treatment of adult patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusion genes or rearrangements. How effective is the treatment for cholangiocarcinoma?

Cholangiocarcinoma is a highly malignant tumor with strong invasiveness and poor prognosis. Many patients have lost the chance of surgery when diagnosed. Systemic treatment options for advanced cholangiocarcinoma are extremely scarce. The objective response rate (ORR) of first-line standard chemotherapy is only 15%-26%. Drug resistance often occurs, and there is no standard second-line treatment option. There is an urgent need for new treatment options to improve patient survival. In April 2020, the FDA accelerated the approval of the marketing application for the targeted drug pemetinib for the treatment of patients with previously treated advanced cholangiocarcinoma with FGFR2 gene fusion/rearrangement. As the first targeted drug for cholangiocarcinoma, pemetinib is expected to change the clinical treatment landscape for patients with cholangiocarcinoma.

The accelerated approval of pemetinib, a targeted drug for the treatment of cholangiocarcinoma, was based on the significant efficacy of pemetinib in the phase II clinical trial. Below is the data from the study. The phase II clinical trial of advanced cholangiocarcinoma enrolled 146 patients with advanced cholangiocarcinoma who failed first-line treatment. The study results show that pemetinib treated patients with FGFR2 fusion or rearrangement, the objective response rate (ORR) was 35.5%, of which the disease control rate (DCR) was 82%; the median duration of response (DCR) was 7.5 months; the number of patients with complete response (CR) reached 2.8%; it significantly improved the patient's median survival (OS: 21.1 months) and median progression-free survival (PFS: 6.9 months). It works quickly in clinical practice and has long-lasting curative effect.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.